15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $35.5B | $598M | 3.2% | 0.3% | 5.4% | 3.2% | -$93M | $1.8B | $328M |
| 2024 | $39.3B | $1.1B | 4.5% | 1.5% | 10.2% | 5.9% | $464M | $2.1B | $795M |
| 2023 | $45.6B | $1.9B | 5.2% | 2.9% | 18.2% | 10.0% | $2.7B | $1.8B | $1.8B |
| 2022 | $47.8B | $1.7B | 4.5% | 2.4% | 17.8% | 8.9% | $1.6B | $1.7B | $794M |
| 2021 | $38.4B | $554M | 2.5% | 0.5% | 6.1% | 3.2% | $440M | $1.6B | $413M |
| 2020 | $28.4B | $422M | 3.5% | 1.0% | 4.8% | 2.6% | $669M | $1.8B | $141M |
| 2019 | $31.9B | $830M | 4.3% | 2.1% | 9.6% | 5.0% | $697M | $1.8B | $211M |
| 2018 | — | $776M | — | — | 9.5% | 4.7% | $719M | $1.9B | $451M |
| 2017 | — | $72M | — | — | 0.9% | 0.5% | $510M | $2.1B | $181M |
| 2016 | — | $383M | — | — | 4.9% | 2.2% | $568M | $2.2B | $290M |
| 2015 | — | $781M | — | — | 10.2% | 5.1% | -$617M | $1.3B | $968M |
| 2014 | — | $1.1B | — | — | 16.8% | 7.1% | $522M | $1.5B | $2.1B |
| 2013 | — | $992M | — | — | 19.3% | 7.3% | $1.9B | $1.6B | $1.8B |
| 2012 | — | $1.3B | — | — | 28.3% | 9.2% | $250M | $1.4B | $314M |
| 2011 | — | $961M | — | — | 21.6% | 7.9% | -$9M | $1.5B | $938M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| May '26 | $6.1B | $267M | 6.8% | 1.8% | 2.4% | 1.3% | $985M | — | $498M |
| Feb '26 | $3.3B | -$147M | 0.8% | -7.2% | -1.3% | -0.7% | -$674M | — | $248M |
| Nov '25 | $8.9B | $260M | 4.4% | 1.4% | 2.3% | 1.3% | -$454M | $1.8B | $375M |
| Aug '25 | $8.6B | $197M | 3.8% | 0.6% | 1.8% | 1.0% | $1.1B | $1.8B | $328M |
| May '25 | $4.7B | $232M | 7.0% | 1.5% | 2.2% | 1.2% | $521M | $2.0B | $324M |
| Feb '25 | $3.2B | -$76M | 2.4% | -5.4% | -0.7% | -0.4% | -$1.2B | $2.0B | $433M |
| Nov '24 | $9.3B | $245M | 4.3% | 1.5% | 2.3% | 1.3% | -$487M | $2.2B | $450M |
| Aug '24 | $9.2B | $112M | 3.0% | -0.3% | 1.0% | 0.6% | $846M | $2.1B | $795M |
| May '24 | $9.6B | $297M | 4.9% | 1.6% | 2.7% | 1.6% | $362M | $1.7B | $310M |
| Feb '24 | $9.1B | $170M | 4.0% | 0.7% | 1.6% | 0.9% | -$453M | $1.7B | $633M |
| Nov '23 | $11.4B | $523M | 5.7% | 3.4% | 4.9% | 2.6% | -$290M | $1.8B | $1.3B |
| Aug '23 | $9.5B | $278M | 4.6% | 1.6% | 2.7% | 1.5% | $1.1B | $1.8B | $1.8B |
| May '23 | $12.0B | $547M | 5.6% | 3.3% | 5.4% | 2.9% | $1.8B | $1.8B | $997M |
| Feb '23 | $11.3B | $292M | 3.4% | 1.3% | 3.0% | 1.4% | $83M | $1.8B | $462M |
| Nov '22 | $12.8B | $783M | 6.9% | 5.0% | 8.0% | 3.7% | -$303M | $1.7B | $636M |
| Aug '22 | $13.4B | $431M | 5.2% | 2.9% | 4.6% | 2.3% | $1.8B | $1.7B | $794M |
| May '22 | $13.1B | $577M | 4.9% | 3.1% | 5.9% | 2.8% | $1.2B | $1.8B | $369M |
| Feb '22 | $10.3B | $219M | 2.6% | 0.2% | 2.3% | 1.1% | -$1.2B | $2.0B | $212M |
| Nov '21 | $10.9B | $452M | 4.8% | 2.9% | 4.9% | 2.3% | -$258M | $1.6B | $310M |
| Aug '21 | $10.5B | $249M | 3.4% | 1.2% | 2.8% | 1.4% | $1.3B | $1.6B | $413M |
Over the past 5 years, CHS INC's revenue has grown 4.5% per year, and net income grown 7.2% per year. These are computed facts, not advice.
As of FY2025, CHS INC reported $1.8B of total debt against $328M of cash; operating income covered interest expense 0.6×.
In FY2025, gross margin was 3.2%, operating margin 0.3%, and net margin 1.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.